Production (Stage)
E
XORTX Therapeutics Inc. XRTX.V
TSX
Recommendation
Prev Close
$1.31
Volume
--
Avg Vol (90D)
6,106
Market Cap
$3.58M
Dividend & Yield
--
52-Week Range
$1.15 - $3.88
P/E (TTM)
--
EPS (TTM)
-$0.2963
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
XORTX Therapeutics Announces $3 Million Offering to Advance Gout Programs
5/19/2025 - TipRanks Financial Blog
XORTX Therapeutics looks to raise $3M through private placement
5/19/2025 - SeekingAlpha.com: All News
XORTX Therapeutics looks to raise $3M through private placement
5/19/2025 - Seeking Alpha - Healthcare
Xortx Therapeutics prices 3.41M units at 88c in private placement
5/19/2025 - The Fly
XORTX Announces USD $3 Million Offering
5/19/2025 - Globe Newswire
XORTX Therapeutics Reports Q1 2025 Financial Results
5/16/2025 - TipRanks Financial Blog
Xortx Therapeutics provides update on FDA Type B meeting request
4/30/2025 - The Fly
XORTX Provides Update on FDA Type B Meeting Request
4/30/2025 - Globe Newswire
Xortx Therapeutics announces grant of European patent
4/28/2025 - The Fly
XORTX Announces Grant of European Patent
4/28/2025 - Globe Newswire
XORTX Therapeutics (XRTX) Faces Nasdaq Compliance Challenge
4/18/2025 - GuruFocus
XORTX Therapeutics receives Nasdaq notice for non-compliance
4/18/2025 - SeekingAlpha.com: All News
XORTX Therapeutics receives Nasdaq notice for non-compliance
4/18/2025 - Seeking Alpha - Healthcare
XORTX Therapeutics (XRTX) Notified of Nasdaq Minimum Bid Price Non-Compliance XRTX Stock News
4/18/2025 - GuruFocus
XORTX Receives Nasdaq Notification for Minimum Bid Price Deficiency
4/18/2025 - TipRanks Financial Blog
Xortx Therapeutics discloses Nasdaq notification regarding minimum bid price
4/17/2025 - The Fly
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
4/17/2025 - Globe Newswire
XORTX Therapeutics Releases Annual Information Form for 2024
4/1/2025 - TipRanks Financial Blog
Xortx Therapeutics to provide Type B meeting package to FDA during next week
3/19/2025 - The Fly
XORTX Announces Update for Discussion with the FDA
3/19/2025 - Globe Newswire
Xortx Therapeutics commences gout program NDA discussions with FDA
2/24/2025 - The Fly
XORTX Commences Gout Program NDA Discussions with the FDA
2/24/2025 - Globe Newswire
ARMISTICE CAPITAL, LLC Acquires Shares in XORTX Therapeutics Inc
2/15/2025 - GuruFocus
XORTX to Present at Microcap Conference
1/29/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$3.08M
EBIT (TTM)
-$2.79M
Net Income (TTM)
-$993.10K
Balance Sheet
Total Assets (Q)
$3.50M
Total Debt (Q)
$15.70K
Total Liabilities (Q)
$757.40K
Book Value Per Share (Q)
$0.7236
Cash Flow
Cash from Operations (TTM)
-$3.02M
Cash from Investing (TTM)
-$39.70K
Cash from Financing (TTM)
$1.14M
Net Change in Cash (TTM)
-$1.94M
Filings
Filing Date
Friday, May 16, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 11 and 15 (est)
Price History
Loading...
Beta
-1.10
7-Day Total Return
9.16%
30-Day Total Return
24.35%
60-Day Total Return
0.70%
90-Day Total Return
-9.49%
Year to Date Total Return
-13.86%
1-Year Total Return
-59.14%
2-Year Total Return
-85.29%
3-Year Total Return
-90.49%
5-Year Total Return
-91.80%
52-week Low
Apr 11, 2025 - $1.15
52-week High
May 24, 2024 - $3.88
Valuation
Market Cap
$3.58M - Nano Cap
Enterprise Value
$1.63M
Price/Sales (TTM)
--
Price/Book (Q)
1.81
Dividends and Shares
Shares Outstanding
3.74M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.xortx.com
Phone Number
403-455-7727
Address
3710 – 33rd Street NW
Calgary, AB T2L 2M1
Country
Canada
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug... more